sales@dcchemicals.com
C18 NC-TNP
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| C18 NC-TNP | 60 | noncationic_lipid |
| Cholesterol | 40 | Sterol |
| Reported total | 100 | Source values retained |
Component molecular weights and calculated amounts
Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| C18 NC-TNP | 60.000 | 95.8735 | 75.2870 | ||
| Cholesterol | 40.000 | 63.9157 | 24.7130 |
Calculated total: 100.0000 mg lipid.
Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.
Literature-reported performance for the cited formulation
Literature-reportedC18 NC-TNP produced higher EGFP expression than the SM-102 benchmark in the reported cell models.C18 NC-TNP/cholesterol 60:40 mol%; EGFP mRNA 1 µg/mL; 48 h · SM-102:DSPC:cholesterol:DMG-PEG 50:10:38.5:1.5 mol%PMC article, Fig. 1 and Results; main text
Literature-reportedThe article reports preferential spleen accumulation and a higher spleen/liver ratio than the benchmark LNP in the IV Cy5-labelled study.Cy5-labelled nanoparticle IV mouse study · SM-102 LNPPMC article, Fig. 4
Literature-reportedOVA mRNA nanoparticles induced antigen-specific cellular and humoral responses, with durable immune-memory claims in the reported immunization schedule.OVA mRNA 1 mg/kg; SC or IV mouse immunization; day 0/7/14 schedule where stated · SM-102 benchmark and study controlsPMC article, Fig. 5 and In Vivo Immune Responses
Literature-reportedLiquid and lyophilized formulations retained reported activity during the tested 30-day storage comparison at 4 °C.Formulated nanoparticles, 4 °C, 30 days · Fresh formulationPMC article, storage-stability section
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetWang et al. Biomimetic noncationic lipid nanoparticles for mRNA delivery. Proc Natl Acad Sci U S A. 2023;120(51):e2311276120.
Quantitative and qualitative performance claims apply to the cited C18 NC-TNP/cholesterol nanoparticle formulations and mouse/cell assays, not to the neat lipid alone.
Quantitative and qualitative performance claims apply to the cited C18 NC-TNP/cholesterol nanoparticle formulations and mouse/cell assays, not to the neat lipid alone.